Syntegon sells Waiblingen property and plans further growth with new locations
Focused pharmaceutical site in Fellbach creates new production capacities
Syntegon continues its successful development and prepares for the next phase of its growth course. With the sale of its previous site in Waiblingen to Andreas Stihl AG & Co KG and the relocation of its production and administration activities to Fellbach and Bad Cannstatt (Stuttgart) planned for this year, Syntegon is creating the ideal conditions for further growth.
Syntegon is moving into a focused pharmaceutical site in Fellbach this year.
Syntegon
Modern pharmaceutical site in Fellbach
The activities of the Pharma Solid division based in Waiblingen will move to a specific pharmaceutical site in neighboring Fellbach in the second half of 2025. A modern production center will be built there, which will significantly increase production capacity and thus enable further growth. The site will have an optimized production and office concept that is geared towards the needs of the growing pharmaceutical industry.
Business Excellence Center in Bad Cannstatt
Syntegon will relocate the Group's central administrative functions to the Business Excellence Center in Bad Cannstatt, Stuttgart, in the third quarter of 2025. From there, they will provide optimal support for the Syntegon Group's global expansion under modern working conditions. The sustainably developed office building is located a short distance from Stuttgart's main railway station and airport.
Waiblingen property in good hands
Syntegon is selling its previous location on Stuttgarter Strasse in Waiblingen to Andreas Stihl AG & Co KG. Both parties signed a corresponding purchase agreement on March 31. "We are delighted that our long-standing property is passing into good hands," says Torsten Türling, Chief Executive Officer of the Syntegon Group.
Future-oriented strategy
The spatial changes mark an important step in the implementation of Syntegon's growth strategy. "With the new locations in Fellbach and Bad Cannstatt, we are creating the ideal conditions for further growth and are even better able to live up to our claim of being a strategic technology partner to the global pharmaceutical industry," says Torsten Türling.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of current news. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
Other news from the department business & finance
